引用本文: | 胡毅, 刘思阳. 非小细胞肺癌患者PD-1通路抑制剂客观缓解率低与EGFR突变或ALK阳性有关[J]. 循证医学, 2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013 |
Citation: | HU Yi, LIU Si-yang. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(1): 46-49. DOI: 10.12019/j.issn.1671-5144.2017.01.013 |